Morgan Stanley
KPTI icon

Morgan Stanley’s Karyopharm Therapeutics KPTI Stock Holding History

Morgan Stanley’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103K Buy
18,570
+9,712
+110% +$74K ﹤0.01% 6147
2025
Q4 		$65.2K Sell
8,858
-16,908
-66% -$103K ﹤0.01% 6355
2025
Q3 		$169K Buy
25,766
+675
+3% +$3.63K ﹤0.01% 5952
2025
Q2 		$108K Buy
25,091
+14,668
+141% +$72K ﹤0.01% 6098
2025
Q1 		$39K Sell
10,423
-223,790
-96% -$1.91M ﹤0.01% 6355
2024
Q4 		$2.38M Buy
234,213
+225,970
+2,741% +$2.73M ﹤0.01% 4581
2024
Q3 		$103K Sell
8,243
-5,091
-38% -$63.3K ﹤0.01% 6001
2024
Q2 		$174K Sell
13,334
-6,318
-32% -$105K ﹤0.01% 5742
2024
Q1 		$445K Sell
19,652
-93,035
-83% -$1.63M ﹤0.01% 5366
2023
Q4 		$1.46M Buy
112,687
+43,056
+62% +$580K ﹤0.01% 5116
2023
Q3 		$1.4M Buy
69,631
+41,477
+147% +$931K ﹤0.01% 4607
2023
Q2 		$756K Sell
28,154
-20,292
-42% -$874K ﹤0.01% 5002
2023
Q1 		$2.83M Sell
48,446
-37,516
-44% -$1.85M ﹤0.01% 4235
2022
Q4 		$4.38M Buy
85,962
+13,970
+19% +$968K ﹤0.01% 3870
2022
Q3 		$5.9M Sell
71,992
-87,121
-55% -$6.51M ﹤0.01% 3534
2022
Q2 		$10.8M Sell
159,113
-28,391
-15% -$2.6M ﹤0.01% 2999
2022
Q1 		$20.7M Buy
187,504
+116,463
+164% +$14.5M ﹤0.01% 2077
2021
Q4 		$6.85M Sell
71,041
-55,155
-44% -$5.5M ﹤0.01% 3382
2021
Q3 		$11M Buy
126,196
+16,684
+15% +$1.73M ﹤0.01% 2779
2021
Q2 		$17M Sell
109,512
-3,720
-3% -$540K ﹤0.01% 2335
2021
Q1 		$17.9M Buy
113,232
+63,704
+129% +$13.4M ﹤0.01% 2032
2020
Q4 		$11.5M Buy
49,528
+20,489
+71% +$4.75M ﹤0.01% 2363
2020
Q3 		$6.36M Buy
29,039
+17,078
+143% +$4.18M ﹤0.01% 2479
2020
Q2 		$3.4M Buy
11,961
+7,989
+201% +$2.36M ﹤0.01% 3065
2020
Q1 		$1.15M Sell
3,972
-3,566
-47% -$984K ﹤0.01% 3847
2019
Q4 		$2.17M Sell
7,538
-3,438
-31% -$746K ﹤0.01% 3971
2019
Q3 		$1.58M Buy
10,976
+3,298
+43% +$447K ﹤0.01% 3986
2019
Q2 		$690K Sell
7,678
-3,276
-30% -$263K ﹤0.01% 4433
2019
Q1 		$960K Buy
10,954
+5,230
+91% +$580K ﹤0.01% 4135
2018
Q4 		$804K Sell
5,724
-889
-13% -$150K ﹤0.01% 4444
2018
Q3 		$1.69M Sell
6,613
-605
-8% -$167K ﹤0.01% 4145
2018
Q2 		$1.84M Sell
7,218
-2,623
-27% -$649K ﹤0.01% 4154
2018
Q1 		$1.98M Buy
9,841
+5,179
+111% +$1.03M ﹤0.01% 4020
2017
Q4 		$671K Buy
4,662
+559
+14% +$89.8K ﹤0.01% 4809
2017
Q3 		$675K Buy
4,103
+2,034
+98% +$291K ﹤0.01% 4691
2017
Q2 		$281K Sell
2,069
-1,660
-45% -$246K ﹤0.01% 5146
2017
Q1 		$718K Sell
3,729
-3,108
-45% -$499K ﹤0.01% 4613
2016
Q4 		$964K Buy
6,837
+5,645
+474% +$763K ﹤0.01% 4488
2016
Q3 		$175K Buy
1,192
+848
+247% +$102K ﹤0.01% 5075
2016
Q2 		$35K Sell
344
-1,089
-76% -$141K ﹤0.01% 5653
2016
Q1 		$192K Buy
1,433
+141
+11% +$15.6K ﹤0.01% 4996
2015
Q4 		$257K Sell
1,292
-7,604
-85% -$1.65M ﹤0.01% 4952
2015
Q3 		$1.41M Buy
8,896
+6,846
+334% +$1.83M ﹤0.01% 3821
2015
Q2 		$837K Sell
2,050
-1,799
-47% -$778K ﹤0.01% 4337
2015
Q1 		$1.77M Buy
3,849
+662
+21% +$285K ﹤0.01% 3687
2014
Q4 		$1.79M Sell
3,187
-49
-2% -$27.8K ﹤0.01% 3664
2014
Q3 		$1.7M Buy
3,236
+221
+7% +$125K ﹤0.01% 3576
2014
Q2 		$2.11M Buy
3,015
+2,003
+198% +$932K ﹤0.01% 3444
2014
Q1 		$469K Sell
1,012
-6,953
-87% -$3.52M ﹤0.01% 4606
2013
Q4 		$2.74M Buy
+7,965
New +$2.2M ﹤0.01% 3139

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Morgan Stanley's KPTI Position: Q1 2026 in Review

Morgan Stanley increased its Karyopharm Therapeutics (KPTI) stake by 110% in Q1 2026, buying an estimated $74K and bringing the position to 18,570 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #6147.

Morgan Stanley first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $20.7M in Q1 2022. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Morgan Stanley held 18,570 shares of Karyopharm Therapeutics worth $103K as of Q1 2026.
  • Morgan Stanley bought 9,712 Karyopharm Therapeutics shares in Q1 2026, an estimated $74K.
  • Karyopharm Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6147 holding.
  • Morgan Stanley first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Morgan Stanley's Karyopharm Therapeutics position peaked at $20.7M in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.